+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID05461768

Evaluating Safety, Dosage, and Preliminary Effects of BL-M07D1 in Patients with Advanced or Metastatic HER2-Positive or Low-Expression Breast Cancer and Other Solid Tumors

Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-08-27

348

Participants Needed

7

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of the drug BL-M07D1 in patients with locally advanced or metastatic HER2-positive or low-expression breast cancer and other solid tumors. This study aims to determine the dose-limiting toxicity and maximum tolerated dose in an initial phase Ia, and then further assess safety to recommend a dose for future phase II studies during phase Ib. It also explores preliminary effectiveness, how the drug behaves in the body, and its immune response. Participants receive BL-M07D1 by intravenous infusion during the first treatment cycle lasting three weeks. Those who benefit can continue receiving additional cycles until the disease progresses, intolerable side effects occur, or other reasons for stopping arise. The study consists of a single group receiving the investigational drug without a placebo or comparison treatment. During the study, participants undergo safety monitoring for adverse events and evaluations of drug levels in the body for up to 21 days after the first dose. The research team measures outcomes such as dose-limiting toxicities, maximum tolerated dose, recommended dose for phase II, and treatment-emergent adverse events for up to about 24 months. Other assessments include anti-drug antibodies, tumor response rates, duration of response, and progression-free survival. Participants are monitored closely throughout their involvement, which can last up to approximately two years.

CONDITIONS

Brief Title

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

Research Team

S

Sa Xiao, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here